Cargando…
Palliative oncology and palliative care
New therapeutic approaches can produce promising results even in severely ill cancer patients. But they also pose new challenges with respect to prognostication, as patients who were once not eligible for treatment, due to age or comorbidities, now are. Palliative oncology constitutes a major part o...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533690/ https://www.ncbi.nlm.nih.gov/pubmed/35762045 http://dx.doi.org/10.1002/1878-0261.13278 |
_version_ | 1784802398449958912 |
---|---|
author | Strang, Peter |
author_facet | Strang, Peter |
author_sort | Strang, Peter |
collection | PubMed |
description | New therapeutic approaches can produce promising results even in severely ill cancer patients. But they also pose new challenges with respect to prognostication, as patients who were once not eligible for treatment, due to age or comorbidities, now are. Palliative oncology constitutes a major part of oncological care, with life prolongation and quality of life as its main goals. Palliative care specialists are experts in symptom control and psychosocial and existential support, and the integration of their expertise early on in patient care can prolong survival. In this article, I discuss the need to integrate specialist palliative care into early cancer treatment plans to achieve quality of life for patients. I also discuss the ways in which palliative care specialists balance the benefits of novel treatments against their adverse effects for patients, particularly for the elderly, the frail and those in advance stages of disease. I highlight the need to ensure equal access to palliative care to improve cancer patients' quality of life but also why futile, burdensome treatments should be avoided especially in the frail, elderly patients. Further, I discuss benefits and problems related to nutritional support in patients with cachexia and exemplify why translational research is needed to link basic research with clinical oncology and effective symptom control. |
format | Online Article Text |
id | pubmed-9533690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95336902022-10-11 Palliative oncology and palliative care Strang, Peter Mol Oncol Policy Paper New therapeutic approaches can produce promising results even in severely ill cancer patients. But they also pose new challenges with respect to prognostication, as patients who were once not eligible for treatment, due to age or comorbidities, now are. Palliative oncology constitutes a major part of oncological care, with life prolongation and quality of life as its main goals. Palliative care specialists are experts in symptom control and psychosocial and existential support, and the integration of their expertise early on in patient care can prolong survival. In this article, I discuss the need to integrate specialist palliative care into early cancer treatment plans to achieve quality of life for patients. I also discuss the ways in which palliative care specialists balance the benefits of novel treatments against their adverse effects for patients, particularly for the elderly, the frail and those in advance stages of disease. I highlight the need to ensure equal access to palliative care to improve cancer patients' quality of life but also why futile, burdensome treatments should be avoided especially in the frail, elderly patients. Further, I discuss benefits and problems related to nutritional support in patients with cachexia and exemplify why translational research is needed to link basic research with clinical oncology and effective symptom control. John Wiley and Sons Inc. 2022-08-12 2022-10 /pmc/articles/PMC9533690/ /pubmed/35762045 http://dx.doi.org/10.1002/1878-0261.13278 Text en © 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Policy Paper Strang, Peter Palliative oncology and palliative care |
title | Palliative oncology and palliative care |
title_full | Palliative oncology and palliative care |
title_fullStr | Palliative oncology and palliative care |
title_full_unstemmed | Palliative oncology and palliative care |
title_short | Palliative oncology and palliative care |
title_sort | palliative oncology and palliative care |
topic | Policy Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533690/ https://www.ncbi.nlm.nih.gov/pubmed/35762045 http://dx.doi.org/10.1002/1878-0261.13278 |
work_keys_str_mv | AT strangpeter palliativeoncologyandpalliativecare |